On Monday, April 13, 2020, the NF Community came together via Zoom webinar to 'Sel-u-brate' the announcement of the FDA approval of selumetinib, or Koselugo, the first approved treatment for the rare disease neurofibromatosis. Koselugo is now approved for NF1 patients with inoperable plexiform neurofibromas, and this approval opens the door to future approvals for the other forms of NF, NF2 and schwannomatosis. Researchers and NF Experts speaking in this live Zoom webinar include:

Annette Bakker, PhD, President of the Children's Tumor Foundation (CTF)
Rick Horvitz, CTF Board of Directors Chair
Tracy Galloway, CTF Board Member
Brigitte Widemann, MD, Principal Investigator of the selumetinib clinical trial
Andrea Gross, MD, NF Researcher
Jaishri Blakely, MD, NF Researcher
Simon Vukelj, Chief Marketing Officer (CTF)

Many NF patients and other members of the NF community also joined to 'selu-brate' and provided their reflections on the news.

To learn more about this drug approval, read patient stories, and hear the history of this progress, go to ctf.org/mek

To enable closed captioning, click the CC button.

What is the Children's Tumor Foundation?
Children’s Tumor Foundation (CTF) began as the first grassroots organization solely dedicated to finding treatments for NF. Today, CTF is a highly recognized global nonprofit foundation, the leading force in the fight to end NF, and a model for other innovative research endeavors.

Visit our website at [ Ссылка ]
Donate today at [ Ссылка ]

Follow us on our social media platforms:
Facebook - [ Ссылка ]
Instagram - [ Ссылка ]
Twitter - [ Ссылка ]
LinkedIn - [ Ссылка ]

#endnf #nf1 #nf2 #nf2swn #swn #childrenstumor #neurofibromatosis #schwannomatosis #nervetumor #tumor

свернуть